Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: A summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability-Reference-Cited by-同舟云学术

Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: A summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability

Published:2007-02 Issue:2 Volume:29 Page:290-304
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Thyssen An,Remmerie Bart,D'Hoore Peter,Kushner Stuart,Mannaert Erik

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference31 articles.

1. Size of burden of schizophrenia and psychotic disorders;Rossler;Eur Neuropsychopharmacol,2005

2. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-Month follow-up of theIntercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study;Dossenbach;J Clin Psychiatry,2005

3. Tolerability and patient compliance;Roose;J Clin Psychiatry.,1999

4. Recent technological ad-vances in oral drug delivery—A review;Sastry;Pharm Sci Technol Today,2000

5. Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia;Chue;Can J Psychiatry,2002

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review;International Journal of Environmental Research and Public Health;2021-04-20

2. Optimization and evaluation of venlafaxine hydrochloride fast dissolving oral films;Saudi Pharmaceutical Journal;2020-11

3. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes;Pharmacological Research;2018-11

4. Key acceptability attributes of orodispersible films;European Journal of Pharmaceutics and Biopharmaceutics;2018-04

5. Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia;CNS & Neurological Disorders - Drug Targets;2018-01-19